Generalized pustular psoriasis (GPP) is a severe form of psoriasis. In a subset of patients with GPP, the disease results from deficiency of the interleukin (IL)-36 receptor antagonist (DITRA) due to mutations in the IL36RN gene (OMIM 614204). DITRA is characterized by episodic attacks of GPP associated with fever.1
Secukinumab, a recombinant, fully human IgG1κ monoclonal antibody inhibiting IL-17A and approved for the treatment of psoriasis vulgaris, was recently shown to be efficacious in patients with GPP.2 In this case report, we describe the efficacy of secukinumab treatment in an adolescent with DITRA.
Molho-Pessach V, Alyan R, Gordon D, Jaradat H, Zlotogorski A. Secukinumab for the Treatment of Deficiency of Interleukin 36 Receptor Antagonist in an Adolescent. JAMA Dermatol. 2017;153(5):473–475. doi:10.1001/jamadermatol.2016.5705
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: